SkinBioTherapeutics (LSE:SBTX) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:SBTX SkinBioTherapeutics PLC LSE:SBTX
37 GF Score
Price £0.12
GF Value £0.65
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is SkinBioTherapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

SkinBioTherapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:SBTX vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, SkinBioTherapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SkinBioTherapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SkinBioTherapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where SkinBioTherapeutics's Margin of Safety % (DCF Earnings Based) falls into.


LSE:SBTX
37GF Score
SkinBioTherapeutics PLC LSE:SBTX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SkinBioTherapeutics (LSE:SBTX) Overvalued in 2026?

Based on GuruFocus' analysis, SkinBioTherapeutics stock appears to be undervalued. The current stock price of £0.12 is trading 81.9% below its estimated GF Value™ of £0.65. GuruFocus considers SkinBioTherapeutics to be Possible Value Trap.

Key valuation signals for LSE:SBTX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: £0.65 vs. price of £0.12 (81.9% below fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the LSE:SBTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SkinBioTherapeutics Business Description

Address Bath Lane, The Core, Newcastle Helix, Newcastle upon Tyne, GBR, NE4 5TF
SkinBioTherapeutics PLC is a life science company focused on skin health. It is focused on the development of technology to protect, manage, and restore skin utilizing proteins found in the human microbiota. It is targeting three specific skin healthcare sectors; cosmetics, infection control, and eczema.
37GF Score

Get the complete analysis for LSE:SBTX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12
Price
£0.65
GF Value